Head-To-Head Comparison: Cannabis Science (CBIS) vs. BioTelemetry (BEAT)
Cannabis Science (OTCMKTS: CBIS) and BioTelemetry (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.
This is a summary of current ratings for Cannabis Science and BioTelemetry, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioTelemetry has a consensus price target of $43.50, indicating a potential upside of 70.25%. Given BioTelemetry’s higher possible upside, analysts clearly believe BioTelemetry is more favorable than Cannabis Science.
Risk and Volatility
Cannabis Science has a beta of -4.04, indicating that its share price is 504% less volatile than the S&P 500. Comparatively, BioTelemetry has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
This table compares Cannabis Science and BioTelemetry’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
77.9% of BioTelemetry shares are owned by institutional investors. 9.6% of BioTelemetry shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Cannabis Science and BioTelemetry’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|BioTelemetry||$208.33 million||3.97||$53.43 million||$1.31||19.50|
BioTelemetry has higher revenue and earnings than Cannabis Science. Cannabis Science is trading at a lower price-to-earnings ratio than BioTelemetry, indicating that it is currently the more affordable of the two stocks.
BioTelemetry beats Cannabis Science on 10 of the 10 factors compared between the two stocks.
Cannabis Science Company Profile
Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company’s subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.
BioTelemetry Company Profile
BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company’s research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).
Receive News & Stock Ratings for Cannabis Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannabis Science Inc and related stocks with our FREE daily email newsletter.